Dr. George Tidmarsh, director of the agency’s Center for Drug Evaluation and Research, had been placed on leave last Friday pending an investigation by the HHS Office of Inspector General.

Employers cannot afford complacency or the false comfort of rate caps and blanket No New Laser provisions that disguise risk rather than manage it.

Executives at Aon and Gallagher say that the U.S. labor market still looks strong, but that big increases in U.S. health coverage costs are definitely getting employers' attention.

James Gelfand, the president of ERIC, said draft guidance the U.S. Food and Drug Administration posted Wednesday could create new competition for "biologic" medications.